RAPT Therapeutics Announces Development Plans for RPT904

RAPT Therapeutics ( (RAPT) ) has shared an update.

RAPT Therapeutics announced plans for the development of RPT904, a potential best-in-class anti-IgE antibody, with clinical trials set to begin in the second half of 2025. The company aims to transform treatment approaches for food allergies and chronic spontaneous urticaria, with anticipated milestones over the next two years. The announcement highlights RPT904’s potential advantages over existing treatments, including longer half-life and improved compliance, positioning RAPT Therapeutics as a key player in addressing unmet needs in inflammatory disease treatment.

The most recent analyst rating on (RAPT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.

Spark’s Take on RAPT Stock

According to Spark, TipRanks’ AI Analyst, RAPT is a Underperform.

RAPT Therapeutics’ overall stock score reflects significant challenges, primarily due to its inability to generate revenue and consistent operational losses. The strong equity position in the balance sheet is a positive, but technical indicators suggest a continued downward trend. The negative valuation metrics further highlight the risks associated with the stock.

To see Spark’s full report on RAPT stock, click here.

More about RAPT Therapeutics

RAPT Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing transformative therapies for high-value inflammatory diseases. The company is advancing RPT904, a novel anti-IgE antibody designed for less frequent dosing, targeting conditions such as food allergies and chronic spontaneous urticaria, with significant market opportunities in the U.S.

Average Trading Volume: 947,664

Technical Sentiment Signal: Sell

Current Market Cap: $154.8M

For detailed information about RAPT stock, go to TipRanks’ Stock Analysis page.